| scholarly article | Q13442814 |
| P50 | author | Francesco Dieli | Q37839952 |
| Giorgio Stassi | Q5563510 | ||
| Francesco Di Raimondo | Q37840123 | ||
| Jean-Jacques Fournié | Q42849755 | ||
| Giuliana Guggino | Q56810321 | ||
| Nadia Caccamo | Q56810322 | ||
| Paolo Vigneri | Q57012976 | ||
| Matilde Todaro | Q90524639 | ||
| P2093 | author name string | Diana Di Liberto | |
| Matilde D'Asaro | |||
| Angelo Messina | |||
| Serena Meraviglia | |||
| Valentina Orlando | |||
| Alfredo Salerno | |||
| Carmela La Mendola | |||
| Marisa Spina | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 3260-3268 | |
| P577 | publication date | 2010-02-12 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells | |
| P478 | volume | 184 |
| Q34517192 | Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies |
| Q38730126 | Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer |
| Q44541139 | An unconventional TRAIL to cancer therapy. |
| Q36759195 | Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals Vδ2+ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate |
| Q33815423 | Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model |
| Q38051730 | Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside |
| Q38149725 | At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies |
| Q98735436 | Beneficial Effect of Antibiotics and Microbial Metabolites on Expanded Vδ2Vγ9 T Cells in Hepatocellular Carcinoma Immunotherapy |
| Q92853203 | CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy |
| Q26782520 | CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity |
| Q38283536 | Cancer Immunotherapy Using γδT Cells: Dealing with Diversity |
| Q34677859 | Clinical applications of gamma delta T cells with multivalent immunity |
| Q47146669 | Combining Vγ9Vδ2 T Cells with a Lipophilic Bisphosphonate Efficiently Kills Activated Hepatic Stellate Cells |
| Q47681511 | Comparison of two cytoreductive regimens for αβ-T-cell-depleted haploidentical HSCT in pediatric malignancies: Improved engraftment and outcome with TBI-based regimen |
| Q44222188 | Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment. |
| Q28263221 | Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo |
| Q59350350 | Expansion and Adoptive Transfer of Human Vδ2 T Cells to Assess Antitumor Effects In Vivo |
| Q102059535 | Functional and metabolic dichotomy of murine γδ T cell subsets in cancer immunity |
| Q27027547 | Harnessing the power of Vδ2 cells in cancer immunotherapy |
| Q39396311 | Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity. |
| Q36476114 | Immunotherapy of acute myeloid leukemia based on γδ T cells |
| Q37822747 | Immunotherapy targeting colon cancer stem cells |
| Q55311835 | Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer. |
| Q37354985 | In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice. |
| Q37737540 | Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette-Guérin |
| Q38240851 | Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses |
| Q33855566 | Key Features of Gamma-Delta T-Cell Subsets in Human Diseases and Their Immunotherapeutic Implications |
| Q34372167 | Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy |
| Q34560345 | Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity. |
| Q33891400 | Molecular targets for selective killing of TRAIL-resistant leukemic cells |
| Q39098092 | NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells |
| Q36513477 | New insights into antigen specific immunotherapy for chronic myeloid leukemia |
| Q37423895 | Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia |
| Q35783394 | Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge |
| Q90450109 | Organ Biodistribution of Radiolabelled γδ T Cells Following Liposomal Alendronate Administration in Different Mouse Tumour Models |
| Q34652408 | Plasticity of γδ T Cells: Impact on the Anti-Tumor Response |
| Q57300020 | Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression |
| Q38052064 | Potential of human γδ T cells for immunotherapy of osteosarcoma |
| Q38890450 | Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy. |
| Q28482070 | Retracted: Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis |
| Q39453295 | Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate |
| Q34077388 | Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy |
| Q92304043 | Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions |
| Q38179172 | Targeting gamma delta T cells for cancer immunotherapy: bench to bedside |
| Q47160680 | The Generation of Human γδT Cell-Derived Induced Pluripotent Stem Cells from Whole Peripheral Blood Mononuclear Cell Culture |
| Q90419062 | The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses |
| Q38016451 | The multifunctionality of human Vγ9Vδ2 γδ T cells: clonal plasticity or distinct subsets? |
| Q27030355 | The role of gamma delta T cells in haematopoietic stem cell transplantation |
| Q59806979 | Tissue Adaptations of Memory and Tissue-Resident Gamma Delta T Cells |
| Q38287973 | Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment. |
| Q89295006 | Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer |
| Q37876363 | Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. |
| Q38811197 | Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma |
| Q26849323 | What lessons can be learned from γδ T cell-based cancer immunotherapy trials? |
| Q47440172 | Wnt pathway activator TWS119 enhances the proliferation and cytolytic activity of human γδT cells against colon cancer |
| Q36846801 | Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients |
| Q38271584 | γδ T Cell-Mediated Immune Responses in Disease and Therapy |
| Q37576001 | γδ T cells and their potential for immunotherapy |
| Q38262257 | γδ T cells as a potential tool in colon cancer immunotherapy |
| Q92826000 | γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer |
| Q35634919 | γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes |
Search more.